The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Open accessAbstract
There is substantial evidence that bioenergetic defects and excitotoxicity may play a role in the pathogenesis of Huntington's disease (HD). Potential therapeutic strategies for neurodegenerative diseases in which there is reduced energy metabolism and NMDA-mediated excitotoxicity are the administration of the mitochondrial cofactor coenzyme Q10 and the NMDA antagonist remacemide. We found that oral administration of either coenzyme Q10 or remacemide significantly extended survival and delayed the development of motor deficits, weight loss, cerebral atrophy, and neuronal intranuclear inclusions in the R6/2 transgenic mouse model of HD. The combined treatment, using coenzyme Q10 and remacemide together, was more efficacious than either compound alone, resulting in an approximately 32 and 17% increase in survival in the R6/2 and N171-82Q mice, respectively. Magnetic resonance imaging showed that combined treatment significantly attenuated ventricular enlargement in vivo. These studies further implicate defective energy metabolism and excitotoxicity in the R6/2 and N171-82Q transgenic mouse models of HD and are of interest in comparison with the outcome of a recent clinical trial examining coenzyme Q10 and remacemide in HD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, we and others, by using CoQ10 and remacemide (NMDA antagonist) combination therapy observed significantly improved motor performance and increased survival in the R6/2 and the N-171-82Q transgenic mouse models of HD151, 154.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [151]
In the citing paper
“We also demonstrated that CoQ10 produces neuroprotective effects in transgenic mouse models of ALS and HD150, 151.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [151]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Self-citationDavies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188
Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,287
Self-citationChen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
Self-citationBeal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J., Storey, E., Srivastava, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,026
Self-citationBrowne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Self-citationMcGeer, E. G., & McGeer, P. L. (1976) · Nature · doi:10.1038/263517a0 · Cited by 836
Schilling, G. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.397 · Cited by 772
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
Luthi‐Carter, R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.9.1259 · Cited by 723
Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
Ona, V. O., Li, M., Vonsattel, J. P., Andrews, L. J., Khan, S. Q., Chung, W. M., Frey, A. S., Menon, A., Li, X., Stieg, P. E., et al. (1999) · Nature · doi:10.1038/20446 · Cited by 640
Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557
Self-citationSawa, A., Wiegand, G. W., Cooper, J. K., Margolis, R. L., Sharp, A. H., Lawler, J. F., Greenamyre, J. T., Snyder, S. H., & Ross, C. A. (1999) · Nature Medicine · doi:10.1038/13518 · Cited by 557
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522
Self-citationBrouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy‐Willig, A., Kowall, N. W., & Beal, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7105 · Cited by 485
Self-citationJenkins, B. G., Koroshetz, W. J., Beal, M. F., & Rosen, B. R. (1993) · Neurology · doi:10.1212/wnl.43.12.2689 · Cited by 479
Self-citationEnergetics in the pathogenesis of neurodegenerative diseases
Beal, M. F. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01584-8 · Cited by 475
Self-citationEnergy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Self-citationPolyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1
Lin, X., Antalffy, B., Kang, D., Orr, H. T., & Zoghbi, H. Y. (2000) · Nature Neuroscience · doi:10.1038/72101 · Cited by 374
Huntington aggregates may not predict neuronal death in Huntington's disease.
Kuemmerle, S., Gutekunst, C., Klein, A., Li, X. J., Li, S. H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · PubMed · Cited by 362
Self-citationExpression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons
Ginsberg, S. D., Hemby, S. E., Lee, V. M. ‐., Eberwine, J. H., & Trojanowski, J. Q. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1 · Cited by 315
A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312
Beal, M. F., Brouillet, E., Jenkins, B. G., Henshaw, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03633.x · Cited by 297
Self-citationAn analysis of the role of coenzyme Q in free radical generation and as an antioxidant
Beyer, R. E. (1992) · Biochemistry and Cell Biology · doi:10.1139/o92-061 · Cited by 251
Ferrante, R. J., Kowall, N. W., Cipolloni, P. B., Storey, E., & Beal, M. F. (1993) · Experimental Neurology · doi:10.1006/exnr.1993.1006 · Cited by 244
Self-citationHansson, O., Petersén, Å., Leist, M., Nicotera, P., Castilho, R. F., & Brundin, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8727 · Cited by 228
Greene, J. G., Porter, R. H. P., Eller, R. V., & Greenamyre, J. T. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03634.x · Cited by 208
Brouillet, M. (1995) · Medical Entomology and Zoology · Cited by 190
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Self-citationIhara, Y., Namba, R., Kuroda, S., SATO, T. A., & Shirabe, T. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90112-3 · Cited by 161
Schulz, J. B., Matthews, R. T., Henshaw, D. R., & Beal, M. F. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00527-7 · Cited by 155
Self-citationLass, A., Forster, M. J., & Sohal, R. S. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00330-x · Cited by 148
Porter, R. H. P., & Greenamyre, J. T. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020614.x · Cited by 136
A controlled trial of remacemide hydrochloride in Huntington's disease
Kieburtz, K. D., Feigin, A., McDermott, M., Como, P. G., Abwender, D. A., Zimmerman, C. F., Hickey, C., Orme, C., Claude, K., Sotack, J., et al. (1996) · Movement Disorders · doi:10.1002/mds.870110310 · Cited by 104
Nishikawa, Y., Takahashi, M. M., Yorifuji, S., Nakamura, Y., Ueno, S., Tarui, S., Kozuka, T., & Nishimura, T. (1989) · Neurology · doi:10.1212/wnl.39.3.399 · Cited by 100
Noack, H., Kube, U., & Augustin, W. (1994) · Free Radical Research · doi:10.3109/10715769409145637 · Cited by 81
Abe, K., Fujimura, H., Nishikawa, Y., Yorifuji, S., Mezaki, T., Hirono, N., Nishitani, N., & Kameyama, M. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb03962.x · Cited by 76
Dyker, A. G., & Lees, K. R. (1999) · Stroke · doi:10.1161/01.str.30.9.1796 · Cited by 46
Antiglutamate therapies in Huntington’s disease
Kieburtz, K. D. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6369-6_9 · Cited by 44
Neurofibrillary tangle parkinsonian disorders?tau pathology andtau genetics
Morris, H. R., Lees, A. J., & Wood, N. W. (1999) · Movement Disorders · doi:10.1002/1531-8257(199909)14:5 · Cited by 44
Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat
Bannan, P. E., Graham, D. I., Lees, K. R., & McCulloch, J. (1994) · Brain Research · doi:10.1016/0006-8993(94)91984-4 · Cited by 40
Ostrowski, R. P. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00406-8 · Cited by 37
Black, M. A., Tremblay, R. G., Mealing, G. A. R., RAY, R. K., Durkin, J. P., Whitfield, J. F., Blosser, J. C., & Morley, P. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65052170.x · Cited by 34
Greene, J. G., Porter, R. H. P., & Greenamyre, J. T. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0007 · Cited by 23
Adenylate cyclase activity in chick retina
Schwarcz, R. M., & Coyle, J. T. (1976) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(76)90019-7 · Cited by 18
- Self-citation
Cited by
Sorted by citations
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi‐Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 847
Ferrante, R. J., Kubilus, J. K., Lee, J.-H., Ryu, H., Beesen, A. A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi‐Carter, R., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-28-09418.2003 · Cited by 705
Self-citationHarper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
Metadata
- Authors
- Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F.
- Affiliations
- Boston University (US)
- NewYork–Presbyterian Hospital (US)
- Harvard University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2002-03-01
- Volume
- 22
- Issue
- 5
- Pages
- 1592-1599
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6758854
- OpenAlex
- W1949056714
- Cited by
- 391
- References
- 50
- Citations by year
- 2025: 8 · 2024: 8 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 10 · 2019: 9 · 2018: 12 · 2017: 7 · 2016: 12 · 2015: 8 · 2014: 23 · 2013: 11 · 2012: 23
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroscience (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29ns037102-02)
- National Institute on Aging (AG 12992, AG 13846, P30AG013846, P01AG012992)
- National Institute of Neurological Disorders and Stroke (NS37102, NS 35255, NS38180, R01NS035255)
- National Center for Complementary and Integrative Health (AT00613, R01AT000613, U01AT000613)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Huntington's disease, coenzyme Q10, remacemide, R6/2 transgenic mice, mitochondrial bioenergetics, excitotoxicity, NMDA receptor antagonism, neuronal intranuclear inclusions, brain atrophy, ventriculomegaly, motor impairment, combination therapy, survival extension
- MeSH terms
- Huntingtin Protein, Acetamides, Administration, Oral, Animals, Behavior, Animal, Body Weight, Brain, Cerebral Ventricles, Coenzymes, Disease Models, Animal, Drug Evaluation, Preclinical, Drug Synergism, Female, Humans, Huntington Disease, Magnetic Resonance Imaging, Male, Mice, Transgenic, Motor Activity, Nerve Tissue Proteins, Nuclear Proteins, Organ Size, Ubiquinone, Survival Rate, Treatment Outcome, Disease Progression, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
